BeiGene, BioAtla in deal for conditionally activated CTLA-4 inhibitor

BioAtla granted BeiGene a license to BA3071 (CAB-CTLA-4), a conditionally activated inhibitor of CTLA-4, that the partners will develop jointly to treat cancer. The companies plan to test the mAb as

Read the full 313 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE